Literature DB >> 23649930

Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome?

Niloofar Fadaki1, Rui Li, Brian Parrett, Grant Sanders, Suresh Thummala, Lea Martineau, Servando Cardona-Huerta, Suzette Miranda, Shih-Tsung Cheng, James R Miller, Mark Singer, James E Cleaver, Mohammed Kashani-Sabet, Stanley P L Leong.   

Abstract

BACKGROUND: Previous studies showed conflicting and inconsistent results regarding the effect of anatomic location of the melanoma on sentinel lymph node (SLN) positivity and/or survival. This study was conducted to evaluate and compare the effect of the anatomic locations of primary melanoma on long-term clinical outcomes.
METHODS: All consecutive cutaneous melanoma patients (n=2,079) who underwent selective SLN dissection (SLND) from 1993 to 2009 in a single academic tertiary-care medical center were included. SLN positive rate, disease-free survival (DFS), and overall survival (OS) were determined. Kaplan-Meier survival, univariate, and multivariate analyses were performed to determine predictive factors for SLN status, DFS, and OS.
RESULTS: Head and neck melanoma (HNM) had the lowest SLN-positive rate at 10.8% (16.8% for extremity and 19.3% for trunk; P=0.002) but had the worst 5-year DFS (P<0.0001) and 5-year OS (P<0.0001) compared with other sites. Tumor thickness (P<0.001), ulceration (P<0.001), HNM location (P=0.001), mitotic rate (P<0.001), and decreasing age (P<0.001) were independent predictive factors for SLN-positivity. HNM with T3 or T4 thickness had significantly lower SLN positive rate compared with other locations (P≤0.05). Also, on multivariate analysis, HNM location versus other anatomic sites was independently predictive of decreased DFS and OS (P<0.001). By Kaplan-Meier analysis, HNM was associated significantly with the worst DFS and OS.
CONCLUSIONS: Primary melanoma anatomic location is an independent predictor of SLN status and survival. Although HNM has a decreased SLN-positivity rate, it shows a significantly increased risk of recurrence and death as compared with other sites.

Entities:  

Mesh:

Year:  2013        PMID: 23649930     DOI: 10.1245/s10434-013-2977-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

1.  A retrospective analysis of the role of adjuvant radiotherapy in the treatment of cutaneous melanoma.

Authors:  Aaron Baker; Fabian Camacho; Genevieve Andrews; Heath Mackley
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

Review 2.  Clinical utilities and biological characteristics of melanoma sentinel lymph nodes.

Authors:  Dale Han; Daniel C Thomas; Jonathan S Zager; Barbara Pockaj; Richard L White; Stanley Pl Leong
Journal:  World J Clin Oncol       Date:  2016-04-10

3.  Stratifying SLN incidence in intermediate thickness melanoma patients.

Authors:  James M Chang; Heidi E Kosiorek; Amylou C Dueck; Stanley P L Leong; John T Vetto; Richard L White; Eli Avisar; Vernon K Sondak; Jane L Messina; Jonathan S Zager; Carlos Garberoglio; Mohammed Kashani-Sabet; Barbara A Pockaj
Journal:  Am J Surg       Date:  2017-12-14       Impact factor: 2.565

4.  Association of sentinel lymph node biopsy with survival for head and neck melanoma: survival analysis using the SEER database.

Authors:  Steven M Sperry; Mary E Charlton; Nitin A Pagedar
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-12       Impact factor: 6.223

Review 5.  [Malignant head and neck melanoma: Part 2: Therapy].

Authors:  C Pföhler; T Vogt; C S L Müller
Journal:  HNO       Date:  2015-08       Impact factor: 1.284

6.  Red meat and fruit intake is prognostic among patients with localized cutaneous melanomas more than 1mm thick.

Authors:  Bonnie E Gould Rothberg; Kaleigh J Bulloch; Judith A Fine; Raymond L Barnhill; Marianne Berwick
Journal:  Cancer Epidemiol       Date:  2014-09-05       Impact factor: 2.984

7.  Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients.

Authors:  Charles M Balch; John F Thompson; Jeffrey E Gershenwald; Seng-Jaw Soong; Shouluan Ding; Kelly M McMasters; Daniel G Coit; Alexander M M Eggermont; Phyllis A Gimotty; Timothy M Johnson; John M Kirkwood; Stanley P Leong; Merrick I Ross; David R Byrd; Alistair J Cochran; Martin C Mihm; Donald L Morton; Michael B Atkins; Keith T Flaherty; Vernon K Sondak
Journal:  Ann Surg Oncol       Date:  2014-02-15       Impact factor: 5.344

8.  [Treatment of cutaneous malignant melanoma in the head and neck region : An update].

Authors:  B Frerich
Journal:  HNO       Date:  2018-11       Impact factor: 1.284

9.  Dermoscopic and clinical features of head and neck melanoma.

Authors:  Fatma Pelin Cengiz; Abdurrahman Bugra Cengiz; Nazan Emiroglu; Ela Comert; Rainer Hofmann Wellenhof
Journal:  An Bras Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.896

10.  Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.

Authors:  Robert H I Andtbacka; Sanjiv S Agarwala; David W Ollila; Sigrun Hallmeyer; Mohammed Milhem; Thomas Amatruda; John J Nemunaitis; Kevin J Harrington; Lisa Chen; Mark Shilkrut; Merrick Ross; Howard L Kaufman
Journal:  Head Neck       Date:  2016-07-13       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.